Vivos Therapeutics, INC 8-K filings

Vivos Therapeutics announced the issuance of a new US Patent (No. 12,697,190) that broadens protection for its Vivos CARE oral medical device technology, a continuation of its 2024 foundational patent.

Vivos Therapeutics, Inc. announces the departure of its CFO, Bradford Amman, and the appointment of Roman Franklin as interim CFO through a services agreement with The CFO Portal, LLC.

Vivos Therapeutics, Inc. announced the closing of a $2.1 million private placement, issuing units of preferred stock and warrants to V-Co Investors 4 LLC and Bigger Capital Fund, LP.

Vivos Therapeutics has extended the deadline for its $4.5 million debt-to-equity conversion agreement with Streeterville Capital to August 31, 2026.

Vivos Therapeutics plans to raise capital through a proposed rights offering of transferable subscription rights to shareholders.

Vivos Therapeutics announces a binding agreement to exchange up to $4.5 million in debt for equity with Streeterville Capital, aiming to improve stockholder equity and address Nasdaq listing requirements, while also securing a new $5 million convertible note from V-Co Investors 4 LLC.

Vivos Therapeutics has been notified by Nasdaq that it fails to meet the minimum stockholders' equity requirement for continued listing.

Vivos Therapeutics reported $17.5 million in 2025 revenue, driven by sleep testing services and the acquisition of The Sleep Center of Nevada.

Vivos Therapeutics, Inc. announced the closing of a private placement offering, raising $850,000 in cash and converting $1.4 million from a bridge note, to be used for general working capital.

Vivos Therapeutics, Inc. announced the appointment of Gregg C. E. Johnson as an independent director to its Board, effective February 4, 2026.

Vivos Therapeutics completed an inducement transaction, generating $4.6 million in gross proceeds from warrant exercises and issuing new warrants.

Vivos Therapeutics obtained a convertible promissory note for up to $5 million from V-Co Investors 3 LLC to support a proposed $5.5 million equity financing.

Vivos Therapeutics announced the grand opening of its latest sleep testing and treatment center in Auburn Hills, Michigan, expanding its national presence through a capital-efficient affiliation model.

Vivos Therapeutics, Inc. entered into a $2.09 million promissory note agreement with Avondale Capital, securing $1.5 million in net proceeds for working capital.

Vivos Therapeutics announced significant revenue growth in Q3 2025, driven by its strategic pivot to medical sleep practices and the first full quarter of Sleep Center of Nevada operations.

Vivos Therapeutics, Inc. announced the successful re-election of its board of directors, approval of an equity incentive plan amendment, and ratification of its independent auditor at its 2025 Annual Meeting.

Vivos Therapeutics, Inc. increased the aggregate offering price of its common stock under an At The Market offering agreement to up to $3,583,686.

Vivos Therapeutics announced peer-reviewed data confirming its DNA appliance is safe and effective for treating obstructive sleep apnea in children, published in the European Journal of Pediatrics.

Vivos Therapeutics, Inc. announced the continuation of its At The Market offering, allowing it to sell up to $5.8 million in common stock.

Vivos Therapeutics completes the acquisition of The Sleep Center of Nevada, marking a strategic shift to a direct-to-patient model for obstructive sleep apnea treatment, while also detailing new management collaborations and associated risks.

Vivos Therapeutics reports a significant increase in Q2 2025 operating losses to $4.9 million, driven by a strategic pivot and the acquisition of The Sleep Center of Nevada.

Vivos Therapeutics, Inc. has successfully acquired the operating assets of The Sleep Center of Nevada, marking a significant pivot in its business model and securing over $11 million in new debt and equity financing to fund the acquisition and support future growth.

Vivos Therapeutics, Inc. has appointed Baker Tilly US, LLP as its new independent registered public accounting firm following the merger of its previous auditor, Moss Adams LLP, with Baker Tilly, though the prior audit report included a going concern uncertainty.

Vivos Therapeutics has entered into a $1.1 million convertible promissory note agreement with V-Co Investors 2 LLC to support the pending acquisition of The Sleep Center of Nevada.

Vivos Therapeutics announces its Q1 2025 financial results, showcasing an 8% increase in product revenue and a 5% decrease in operating expenses, while strategically positioning itself with the pending acquisition of The Sleep Center of Nevada.

Vivos Therapeutics is set to acquire The Sleep Center of Nevada, aiming to broaden the availability of its obstructive sleep apnea (OSA) treatments in the Las Vegas area.

Vivos Therapeutics announces its full year 2024 financial results, showcasing a 26% increase in product revenue and a 35% reduction in operating loss.

Vivos Therapeutics has entered into an agreement for an at-the-market offering of common stock up to $3.3 million and amended employment agreements for its CEO and CFO.

Vivos Therapeutics, Inc. has announced a $3.5 million registered direct offering, priced at-the-market, alongside a concurrent private placement of warrants, with proceeds earmarked for working capital and general corporate purposes.

Vivos Therapeutics successfully held its 2024 annual meeting, electing directors, approving a new equity incentive plan, and ratifying its accounting firm.